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chemotherapy. If conﬁrmed on other patient populations, our ﬁndings 
should signiﬁcantly advance the clinical management of patients with 
completely resected NSCLC. 
The study was supported by an unrestricted grant from Eli Lilly.
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MAP4/OP18 mRNA expression predicts progression in patients 
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Background: Non-small-cell lung cancer (NSCLC) patients with 
locally advanced or metastatic disease at the time of diagnosis show 
marginal response to chemotherapy in terms of tumor shrinkage, time 
to progression and median survival. MAP4 and stathmin have been pre-
viously reported as potential markers of resistance to treatment based 
on microtubule-destabilizing agents.
Methods: In this multicenter study, we have used quantitative PCR to 
analyze the expression of MAP4, stathmin, beta-tubulin III, BRCA1 
and ERCC1 using mRNA isolated from peripheral blood samples of 51 
non-small-cell lung cancer patients treated with vinorelbine/carboplatin.
Results: In a preliminary set, 46 patients with stage IIIB and IV 
were analyzed. Lower levels of MAP4/OP18 mRNA expression are 
statistically associated with a response to vinorelbine-based treatment 
(p=0.029). This signiﬁcant relationship is maintained in a second analy-
sis after 3rd cycle of treatment (p=0.032). Higher levels of MAP4/op18 
were associated with a lower TTP (p=0.05).
Conclusions: Our preliminary results suggest that the ratio MAP4/
OP18 may be a good predictor of response for NSCLC patients treated 
with vinorelbine-based chemotherapy.
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Objective: To prospectively evaluate the use of positron emission 
tomography (PET) with the glucose analog 18-ﬂuorodeoxyglucose 
(18FDG) to predict best objective response and survival after the ﬁrst-
line chemotherapy in patients with advanced non-small cell lung cancer 
(NSCLC).
Methods: Patients with advanced NSCLC were prospectively enrolled 
into this study to undergo platinum-based doublet chemotherapy. 
Patients were studied by 18FDG-PET before and after the ﬁrst two 
cycles of chemotherapy. A reduction of tumor 18FDG uptake by more 
than 30% as assessed by standardized uptake value(SUV) was used as 
a criterion for a metabolic response. Compare RECIST response with 
18FDG-PET metabolic response by Measure of Agreement Kappa test.
Survival in patients with or without a metabolic response was com-
pared by the log-rank test. Statistical computations were performed 
with SPSS13.0. 
Results: 46 patients with advanced NSCLC (2 cases with wet stage 
IIIB and 44 cases with stageIV) were included in the study. There was 
a close correlation between metabolic response and best objective 
response to the ﬁrst-line chemotherapy according to RECIST, P<0.001; 
Sensitivity, speciﬁcity, accuracy, prediction of positive value and pre-
diction of negative value for prediction of best objective response were 
95%, 65%, 78%, 69% and 94% respectively. By the end of February 
28, 2007, duration of follow-up had been ranged from 1.8 months to 
29.7 months, median survival time for metabolic responders was 13.70 
months, 95% CI (9.08~13.32), and that for metabolic non-responders 
was 12.00 months, 95% CI (6.58~17.43), P >0.05; there is no differ-
ence in overall survival between metabolic responders and metabolic 
non-responders, P >0.05. 
Conclusions: Reduction of SUV in 18FDG-PET after two-cycle 
chemotherapy for advanced NSCLC is closely correlated with best 
objective response. However, up till now, we have not yet observed 
signiﬁcant difference in median survival time and overall survival time 
between metabolic responders and metabolic non-responders.
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Background: The treatment of non-small-cell lung cancer (NSCLC) 
has reached a plateau of effectiveness, but the selection of patients ac-
cording to key genetic characteristics may help to tailor chemotherapy 
and optimise the treatment increasing response rates and survival. Poly-
morphisms within the Xeroderma Pigmentosum Group D (XPD), Exci-
sion Repair Cross-Complementing 1 (ERCC1) and Cytidine Deami-
nase (CDA) genes have been associated with alterations in enzymatic 
activity and may change sensitivity to the widely used platinum-based 
and gemcitabine chemotherapy regimens. We investigated the correla-
tion between selected single nucleotide polymorphisms (SNPs) of these 
genes and the activity and efﬁcacy of chemotherapy.
Methods: Seventy-eight chemotherapy-naïve, advanced NSCLC 
patients were enrolled in the study; 52 were treated with cisplatin/gem-
citabine and 26, aged > 70 years, with gemcitabine alone. Median age 
was 66 years (range 44-81). Association between XPD Asp312Asn and 
Lys751Gln, ERCC1 C118T and CDA Lys27Gln SNPs and treatment 
response, toxicity, time to progression (TTP) and overall survival (OS) 
was estimated using Kaplan-Meier method, Log-rank test and Cox’s 
proportional model. SNPs were analyzed with the ABI PRISM 7900HT 
Sequence Detection System using TaqMan® probe-based assay in DNA 
obtained from peripheral blood samples.
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Results: In the whole population, CDA Lys27Lys polymorphism sig-
niﬁcantly correlated with better response (P=0.04) and higher haemato-
logical toxicity. In the cisplatin/gemcitabine-treated patients, signiﬁcant 
correlations were observed between CDA Lys27Lys genotype and 
better response, grade >3 neutropenia, as well as with longer TTP and 
OS (P=0.01 and P=0.001, respectively) (Table 1).
Table 1. Correlation between CDA 27 genotype SNP and activity, eﬃcacy 
and haematological toxicity of chemotherapy.
The multivariate analysis conﬁrmed the prognostic signiﬁcance of this 
polymorphism (P=0.02), while no signiﬁcant associations were found 
among ERCC1 and XPD polymorphisms and clinical outcome in this 
group of patients. CDA genotype didn’t result predictive of response 
and toxicity in patients treated with gemcitabine alone.
Conclusions: CDA Lys27Gln polymorphism resulted a predictive 
biomarker of response rate, toxicity, TTP and OS in advanced NSCLC 
patients treated with cisplatin and gemcitabine, thus offering a potential 
new tool for treatment optimization. Enzymatic activity assays on 
blood samples are ongoing to better understand this feature.
This work was partly supported by the Fondazione A.R.C.O.
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Background: Phospholipase D (PLD) is activated by stimulators of 
vesicle transport, endocytosis, exocyosis, cell migration, and mitosis. 
These cellular biological processes are deregulated in the development 
of various human tumors. The involvement of PLD in tumorigenesis 
suggests that PLD could be valuable targets for therapeutic interven-
tion and phamacogenetics focuses on the prediction of the effect 
of chemotherapy by genetic proﬁling in cancers. Single nucleotide 
polymorphisms (SNPs) are extensively used in case-control studies of 
practically all cancer. The identiﬁcation of polymorphisms of cancer 
patients may help the clinician prescribe the optimal drug combination 
or schedule and predict the response of chemotherapy with accuracy.
Method: The purpose of this study was to analyze genetic polymor-
phisms of phospholipase D1(PLD1) gene as a predictive marker for 
response to chemotherapy in non-small cell lung cancer. 
Results: We identiﬁed two SNPs at the exon 14, one SNP at the exon 
16 and six SNPs at the exon 23. cSNPs of PLD1 was selected ac-
cording to the degree of heterozygosity; (exon 23, rs2668, allele A/C: 
A2668C). The allelic frequencies of A2668C was 70.85 % in 211 non-
small lung cancer patients. The allelic frequencies of A2668C polymor-
phism of responders (partial response) showed signiﬁcant association 
with non-responders (stable disease and progression) to chemotherapy 
(p=0.059, OR=1.739). Also, the genotype frequencies of A2668C poly-
morphism of responders showed signiﬁcant association with non-re-
sponders to chemotherapy (p=0.017, OR=2.198). Between gender and 
smoking on the risk of lung cancer, signiﬁcant association was found in 
genotype frequencies of A2668C polymorphism (p=0.013, OR=2.651). 
Conclusion: From our results, we suggest that PLD1 genetic polymor-
phism (A2668C) might be a predictive marker for response to chemo-
therapy in non-small cell Lung cancer. 
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Background: Previously, we reported that small pulmonary adenocar-
cinomas (tumor diameter 20mm or less) could be classiﬁed according 
to attenuation on high-resolution CT (HRCT) images as either ‘air-con-
taining type’ (‘fair-type’) or ‘solid-density type’ (=’solid-type’) (Lung 
Cancer 36 (2002)). Air-type was deﬁned as having areas where tumor 
opacity on mediastinal window images were half or less than half the 
size of those noted on lung window images. Solid-type was deﬁned as 
having areas where tumor opacity on mediastinal window images was 
greater than half the size of those noted on lung window images. Our 
ﬁndings indicated that there was no microscopic evidence of metastasis 
with air-type nor any relapses nor deaths, after resection. By contrast, 
patients with solid-types demonstrated a poor prognosis. At this time, 
the histopathological characteristics of areas of tumor opacity noted on 
mediastinal window images have not been fully investigated.
Method: We retrospectively reviewed the records and CT scans of 118 
patients, who had undergone surgical resection of peripheral adeno-
carcninomas. All tumor diameters were 20mm or less in size. All 118 
patients had undergone HRCT prior to surgery. HRCT Images were 
acquired by a model X-Vigor/Real or an Aquillion CT scanner (Toshiba 
Medical Systems). High-resolution images of tumors were obtained at 
135kVp at 250mAs with 1-2mm section thicknesses. All images were 
photographed using mediastinal (level, 40HU; width, 400HU) and lung 
(level, -600HU; width, 1600HU) window settings. We analyzed the 
correlation between areas of tumor opacity of mediastinal window im-
ages and the histopathological and the clinical ﬁndings.
Results: Areas of tumor opacity noted on mediastinal window images 
demonstrated ﬁve possible histopathological ﬁndings; 1. collapse (C), 
